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Abstract 
Background: The vast majority of stroke burden is attributable to its modifiable risk factors. This paper aimed to sys-
tematically summarise the evidence of Chinese herbal medicine (CHM) interventions on stroke modifiable risk factors 
for stroke prevention.
Methods: A literature search was conducted via the MEDLINE, CINAHL/EBSCO, SCOPUS, and Cochrane Database 
from 1996 to 2016. Randomised controlled trials or cross-over studies were included. Risk of bias was assessed accord-
ing to the Cochrane Risk of Bias tool.
Results: A total of 46 trials (6895 participants) were identified regarding the use of CHM interventions in the manage-
ment of stroke risk factors, including 12 trials for hypertension, 10 trials for diabetes, eight trials for hyperlipidemia, 
seven trials for impaired glucose tolerance, three trials for obesity, and six trials for combined risk factors. Amongst the 
included trials with diverse study design, an intervention of CHM as a supplement to biomedicine and/or a lifestyle 
intervention was found to be more effective in lowering blood pressure, decreasing blood glucose level, helping 
impaired glucose tolerance reverse to normal, and/or reducing body weight compared to CHM monotherapy. While 
no trial reported deaths amongst the CHM groups, some papers do report moderate adverse effects associated with 
CHM use. However, the findings of such beneficial effects of CHM should be interpreted with caution due to the het-
erogeneous set of complex CHM studied, the various control interventions employed, the use of different participants’ 
inclusion criteria, and low methodological quality across the published studies. The risk of bias of trials identified was 
largely unclear in the domains of selection bias and detection bias across the included studies.
Conclusion: This study showed substantial evidence of varied CHM interventions improving the stroke modifiable 
risk factors. More rigorous research examining the use of CHM products for sole or multiple major stroke risk factors 
are warranted.
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Background
Stroke is the second foremost cause of mortality and a 
leading cause of serious disability worldwide [1]. The inci-
dence of stroke continues to rise due to societal and life-
style changes and an aging population [2]. More than 90% 
of the stroke burden is attributable to its modifiable risk 
factors such as high blood pressure, high fasting plasma 
glucose, and high total cholesterol [3]. These stroke risk 
factors are strongly inter-related and some of them are 
simultaneous shown as a combined risk factor in peo-
ple with stroke with higher risk [4, 5]. Previous research 
has clearly demonstrated the benefits of treating risk 
factors such as hypertension, diabetes, hyperlipidemia, 
obesity, atrial fibrillation, or transient ischaemic attack 
(TIA) for reducing the prevalence of primary stroke [6, 
7]. The treatments of major stroke modifiable risk fac-
tors are therefore crucial for informing stroke prevention 
Open Access
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strategies and helping achieve improved quality of life 
of people with those risk factors and lowered associated 
health care costs [3].
Chinese herbal medicine (CHM)—therapies and prod-
ucts made from any part of medicinal plants (e.g. leaves 
and roots) and some non-herb  based components (e.g. 
shells and powdered fossil) [8]—has a history of more 
than 2500  years with a unique theory of diagnosis and 
treatment, and is considered a modality of complemen-
tary medicine in Western countries [9]. CHM has been 
increasingly used for a wide range of chronic diseases in 
China and elsewhere in the form of raw plant materials, 
powers, capsules, tablets and/or liquids [9–11].
Chinese herbal medicine is a field of health care that 
may offer potential for addressing related risk factors of 
stroke [12–14]. Many CHM interventions have long been 
used for the treatments of some stroke risk factors as 
individual diseases such as Type 2 diabetes [15], hyper-
tension [8] and obesity [16]. However, the research evi-
dence as to whether specific CHM therapies or products 
may be effective in reducing each individual or mixed 
major risk factors of stroke remains unclear. The aim of 
this systematic review is to assess and summarize the 
efficacy and safety of all relevant CHM interventions for 
people at greatest risk(s) of stroke.
Methods
Search strategy
Four key bibliographic databases—MEDLINE, CINAHL/
EBSCO, SCOPUS, and Cochrane Database of System-
atic Reviews—were searched in the systematic review. 
This review was designed and conducted in accordance 
with PRISMA (Preferred Reporting Items for System-
atic Reviews and Meta-Analyses) guidelines. The stroke 
modifiable risk factors identified in this systematic review 
refer to high blood pressure (hypertension), high choles-
terol (hyperlipidemia), irregular pulse (atrial fibrillation), 
TIA, high blood glucose (diabetes and impaired glucose 
tolerance (IGT), and overweight (obesity). The literature 
search employed keyword and MeSH term searches for 
terms relevant to ‘CHM’ and terms regarding stroke risk 
factors (Table 1). The combination of the search results of 
CHM and stroke risk factors were identified for screen-
ing. To obtain all relevant articles, reference lists of 
published review papers were also reviewed via Google 
Scholar.
Study selection
The inclusion criteria of literature in the systematic 
review were: peer-reviewed English-language jour-
nal articles focusing upon randomized controlled tri-
als (RCTs) or cross-over studies published in the past 
20  years (1996–2016), and articles reporting primary 
data findings examining the efficacy and safety of any 
type of CHM interventions (e.g. decoction, capsule, 
granule, power) on one or more major modifiable risk 
factors of stroke. Exclusion criteria were (1) published 
RCT protocols of this research area; (2) quasi- or pseudo-
RCTs (3) studies focusing upon the efficacy and safety of 
CHM for treating stroke or post-stroke symptoms; (4) 
studies focusing upon the efficacy and safety of CHM 
for treating the complications of the stroke risk factors; 
Table 1 Search terms for the systematic review
Chinese herbal medicine Chinese herbal medicine [MeSH Term & Keyword] OR Chinese medicine [MeSH Term & Keyword] OR Chinese 
herb* [Title/Abstract] OR Chinese herbal [Title/Abstract]
AND
 Stroke risk factors High blood pressure Hypertension [MeSH Term & Keyword] OR Blood pressure [MeSH Terms & Keyword] OR 
Hypertens* [Title/Abstract] OR Prehypertens* [Title/Abstract] OR Systolic [Title/Abstract] OR 
Diastolic [Title/Abstract] OR
High cholesterol Cholesterol [MeSH Term & Keyword] OR Triglycerides [MeSH Term & Keyword] OR Dyslipi-
demia [MeSH Term & Keyword] OR Epicholesterol [Title/Abstract] OR HDL [Title/Abstract] 
OR LDL [Title/Abstract] OR Triglyceride* [Title/Abstract] OR Hyperlipidem* [Title/Abstract] 
OR Lipidem* [Title/Abstract] OR
Irregular pulse Cardiac arrhythmias [MeSH Terms & Keyword] OR Atrial fibrillation [MeSH Terms & Keyword] 
OR Dysrhythmia* [Title/Abstract] OR Cardiac arrhythmia* [Title/Abstract] OR
Transient ischaemic attack Transient ischaemic attack [MeSH Terms & Keyword] OR Transient ischaemic attack* [Title/
Abstract] OR
High blood glucose Diabetes [MeSH Terms & Keyword] OR Mellitus [MeSH Terms & Keyword] OR Impaired glucose 
tolerance [MeSH Terms & Keyword] OR Diabet* [Title/Abstract] OR NIDDM [Title/Abstract] 
OR IDDM [Title/Abstract] OR T2DM [Title/Abstract] OR *insulin* [Title/Abstract] OR Glucose 
[Title/Abstract] OR
Overweight Obesity [MeSH Terms & Keyword] OR Overweight [MeSH Terms & Keyword] OR Metabolic 
syndrome [MeSH Terms & Keyword] OR Obes* [Title/Abstract] OR Adiposity [Title/Abstract] 
OR Adipos* [Title/Abstract]
* Truncation, refering to all records that have those letters with any ending
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(5) conference abstracts; and (6) publications without 
abstracts.
Data extraction
Titles and abstracts of all citations identified in the ini-
tial search were imported to Endnote (Version X7) and 
duplicates removed. Two of the authors screened all the 
titles/abstracts to identify articles meeting the inclusion 
and exclusion criteria independently. When consensus 
was not reached, the full texts of these unclear papers 
were retrieved and assessed by these two authors. Disa-
greements were discussed with a third author.
Data were extracted into a pre-determined table 
(Table 2) and checked for coverage and accuracy by two 
of the authors. Any differences in data extraction and 
interpretation were resolved through discussion amongst 
all authors. Table  2 includes detailed information on 
study recruitment, participant characteristics, interven-
tion groups, results of primary outcome measures, study 
limitations, and CHM safety.
Quality assessment
Two authors independently assessed the methodological 
quality of the included studies using the Cochrane risk of 
bias criteria [17]. The characteristics of RCTs that might 
be related to selection bias (random sequence generation 
and allocation concealment), performance bias (blinding 
of participants and personnel), detection bias (blinding of 
outcome assessment), attrition bias (incomplete outcome 
data), reporting bias (selective outcome reporting), and 
other bias were evaluated. Disagreements regarding the 
risks of bias of some studies were resolved through dis-
cussion amongst these two authors (Table 3).
Results
The systematic review reported in this paper has been 
registered on the PROSPERO (International prospec-
tive register of systematic reviews, #CRD42017060107). 
The PRISMA flowchart of literature search and study/
article selection has been shown in Fig.  1. A total of 
2377 papers were identified (2374 via database searches 
and three additional papers via Google Scholar). After 
removing duplicates, a total of 2065 papers remained for 
review. From amongst these, 70 manuscripts were identi-
fied for full review following title and abstract screening. 
Further screening of the full texts identified 46 publica-
tions (reporting on 46 RCTs) as eligible for final inclu-
sion in the systematic review. Twelve of the included 
articles report on the efficacy of CHM for hypertension 
(1340 participants), 10 for diabetes (2004 participants), 
eight for hyperlipidaemia (997 participants), seven for 
IGT (1805 participants), three for obesity (329 partici-
pants), and six for the combination of several stroke risk 
factors (420 participants). No manuscript reported on a 
trial investigating the efficacy of CHM interventions for 
the stroke risk factor of transient ischemic attack or atrial 
fibrillation as a primary outcome. The characteristics of 
included studies with regards to the CHM interventions 
for hypertension, diabetes, hyperlipidaemia, IGT, obe-
sity, and combined stroke risk factors are summarized in 
Table 2.
Hypertension
Eight RCTs were focused upon primary (essential) hyper-
tension [18–25], one with isolated systolic [26], one 
with elder polarized hypertension [27], and two with 
hypertension and related cardiovascular diseases [28, 
29]. Of the 12 RCTs on CHM for hypertension, 11 RCTs 
originated from China [18–22, 24–29]. Amongst the 
hypertension-focused RCTs, one RCT compared ‘CHM, 
biomedicine plus lifestyle’ intervention with ‘biomedi-
cine plus lifestyle’ intervention [27] and showed signifi-
cant decreased systolic blood pressure (SBP) before and 
after treatment of both intervention groups and a simi-
lar effect on controlling SBP between these two groups 
after treatment. Another two RCTs compared two differ-
ent CHM interventions using different inclusion crite-
ria of people with hypertension   [19, 21]—these studies 
both reported a significant decrease of SBP and diastolic 
blood pressure (DBP) via all the CHM interventions 
examined with higher effective rate of treatments in the 
CHM groups than those in the control groups. Another 
three RCTs compared ‘CHM’ interventions with ‘bio-
medicine’ interventions and employed consistent inclu-
sion criteria regarding SBP (140–179  mmHg) and DBP 
(90–109 mmHg) of participants, reporting a statistically 
significant decrease of SBP and DBP before and after 
treatment of both groups and a similar effect on control-
ling SBP and DBP between these two groups after treat-
ment [18, 22, 24]. Another six RCTs compared ‘CHM 
plus biomedicine’ interventions with ‘biomedicine alone’ 
or ‘biomedicine plus placebo’ interventions [20, 23, 25, 
26, 28, 29]. It is noteworthy that two of these six trials   
[20, 28] examined the efficacy of the same CHM prod-
ucts (Xuezhikang capsule) at different dose levels, dem-
onstrating a significant decrease of SBP and DBP before 
and after treatment of both intervention groups and a 
silimar effect on SBP and DBP control between these two 
groups after treatment. Also amongst these six RCTs, 
three were three-armed RCTs which compared either 
‘CHM plus biomedicine’ intervention versus ‘biomedi-
cine/no intervention’, ‘CHM’ interventions versus ‘CHM 
plus biomedicine’ or ‘placebo plus biomedicine’ interven-
tion, or two types of preparations of a ‘CHM plus bio-
medicine’ intervention versus ‘placebo plus biomedicine’ 
intervention [25, 26, 28], showing inconsistent findings 
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with regards to the decrease of SBP or DBP amongst the 
three groups after treatment. Gouteng (钩藤) [18, 19, 21, 
24, 25, 29] and Tianma (天麻) [18, 22, 25–27] were the 
most frequently used Chinese herbs in the hypertension-
focused RCTs included, and all the CHM interventions 
using Gouteng and/or Tianma reported significant pre-
post effectiveness regarding the decrease of SBP (and/
or DBP) level. Also, Gouteng was the principal CHM for-
mula constituent amongst four out of six hypertension-
focused RCTs presenting between-group effectiveness 
of the investigated CHM interventions on the decrease 
of SBP (and/or DBP) levels compared to control inter-
ventions [21, 24, 25, 29]. In addition, the sample size of 
hypertension-focused RCTs ranged from 55 to 219. Six 
hypertension-focused RCTs did not provide the age and 
gender profile of the participants in either CHM group 
or control group [20, 22, 23, 26, 27, 29]. The duration of 
the hypertension-focused trials ranged from 2  weeks to 
24 months, with the majority of trials conducted between 
4 and 12 weeks.
Eight hypertension-focused RCTs reported safety-
related information and no deaths were noted [18, 19, 21, 
23, 26–29]. One trial reported five cases of serious side 
effects of the ‘CHM plus biomedicine’ intervention group 
[29]. One trial (sample: 55) reported 13 mild side effects 
in the ‘CHM plus biomedicine’ intervention group and 15 
in the ‘placebo plus biomedicine’ control group [23]. Only 
two of the papers reporting results from hypertension-
focused RCTs listed any study limitations including small 
sample size and short study period [23, 24]. As for risk of 
bias in the hypertension-focused RCTs, three papers pro-






















Records identified through database 
searching
(n=2374) 
Medline               (n=1308) 
Scopus                  (n=329) 
CINAHL/EBSCO   (n=79) 
Cochrane library (n=658)
Additional records identified 
through other sources
(n=3)








Full-text articles assessed 
for eligibility
(n=70)
Full-text articles excluded, 
with reasons
(n=24)
Not randomized controlled 
trial
Not stroke risk factor
Conference abstract
Not suited control group
44 Studies included in 
qualitative synthesis
(46 articles)
Fig. 1 PRISMA flowchart of literature search and study selection
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25] and four on the blinding of outcome assessment [20, 
23–25]. Additionally, only three trials reported double-
blinding of participants and personnel involved [20, 21, 
26].
Diabetes
All of the 10 included diabetes-focused RCTs were focus-
ing upon patients diagnosed with Type 2 diabetes melli-
tus and all these RCTs were conducted in China [30–39]. 
Amongst the 10 RCTs examining the efficacy of CHM 
on controlling the glucose level of patients with diabe-
tes, four RCTs compared ‘CHM’ intervention to ‘placebo’ 
[32], ‘CHM plus biomedicine’ intervention to ‘placebo 
plus biomedicine’ intervention [39], and further, ‘CHM 
plus lifestyle’ intervention to ‘placebo plus lifestyle’ inter-
vention [30, 35]. These four trials indicated more signifi-
cant decreased glucose level [e.g. fasting plasma glucose 
(FPG), 2-hour postprandial glucose (2hPG), glycated 
hemoglobin (HbA1c)] by using CHM products when 
compared to the placebos after treatment, while this sig-
nificant between-group variance in the decrease of glu-
cose level showed no statistical significance when both 
CHM interventions and placebos were used concurrently 
with biomedicine or lifestyle intervention. Also amongst 
these 10 diabetes-focused RCTs, ‘CHM plus biomedi-
cine’ intervention was compared to ‘biomedicine’ inter-
vention, showing a more significant decrease of insulin 
usage by the CHM plus biomedicine treatment after 
treatment [34]. Also, after treatment, ‘CHM, biomedi-
cine plus lifestyle’ interventions were found to achieve a 
more significant decrease of FPG, HbA1c, or hypoglyce-
mia when compared to either ‘biomedicine plus lifestyle’ 
intervention [31, 37] or ‘placebo, biomedicine plus life-
style’ intervention [36, 38]. Of the nine diabetes-focused 
RCTs providing CHM formulas, Huanglian (黄连) was 
the most common Chinese herb [30, 32–34, 36], followed 
by Ginseng (人参) [33, 34, 36, 37], Shanzhuyu (山茱萸) 
[34, 36, 37], Dahuang (大黄) [32, 34, 37], and Huangqi (
黄芪) [30, 34, 37]. The CHM interventions examined in 
three out of five diabetes-focused RCTs, showing sig-
nificant between-group effectiveness on the decrease of 
glucose level, indicated that the combination of these five 
commonly used Chinese herbs played a vital role for the 
efficacy of type 2 diabetes management [34, 36, 37]. All 
diabetes-focused RCTs defined inclusion criteria of dia-
betes based on different FPG, 2hPG, and/or HbA1c lev-
els, and all the tested CHM products used in these RCTs 
were different. The sample size of the diabetes-focused 
RCTs ranged from 43 to 627. Only one RCT provided 
the age and gender profile of participants in the CHM 
and control groups [35]. The duration of the trials ranged 
from 2  weeks to 12  months, with the majority of trials 
conducted between 3–12 months.
Only two diabetes-focused RCTs failed to report 
safety-related information and no death were noted [34, 
36]. The side effects of CHM products reported in the 
diabetes-focused RCTs are generally moderate, such as 
constipation, gastrointestinal disorders, and urinary tract 
infection. However, three diabetes-focused RCTs showed 
that CHM interventions caused slightly abnormal liver 
and kidney function after 3, 6, and 12  months, respec-
tively  [31, 32, 39]. Six diabetes-focused RCTs have speci-
fied their study limitations, with a short study period 
being the most common issue, followed by small sample 
size and no/short follow-up period [32, 33, 35, 36, 38, 39]. 
As for risk of bias of the diabetes-focused RCTs, one trial 
failed to use the random sequence generation method 
[34], three trials did not report information on allocation 
concealment [32, 34, 35], four trials failed to apply a dou-
ble-blinding method [31, 33, 34, 37], and four trials did 
not provide details on the blinding outcome assessment 
[33–35, 37].
Hyperlipidemia
Half of the eight RCTs on CHM for the treatment of 
hyperlipidemia originated from China [40–43]. Amongst 
the hyperlipidemia-focused RCTs, two compared ‘CHM’ 
interventions with ‘biomedicine’ interventions [42, 43], 
two compared different ‘CHM’ interventions [40, 41], 
two compared ‘CHM’ interventions with ‘placebos’ [44, 
45] and two compared ‘CHM plus lifestyle’ interven-
tions with ‘placebo plus lifestyle’ interventions [46, 47]. 
Although the inclusion criteria of people with hyper-
lipidemia shown in the included hyperlipidemia-focused 
RCTs are limited to the total cholesterol (TC), triglyc-
eride (TG), low-density lipoprotein cholesterol (LDL-
C), high-density lipoprotein cholesterol (HDL-C), and/
or body mass index (BMI) levels, the threshold value of 
these indices are diverse across the RCTs. It is worth not-
ing that Monascus purpureus rice preparation (Xuezhi-
kang capsule in Chinese) of which the main ingredient is 
red yeast rice, was tested in four hyperlipidemia-focused 
RCTs [40, 45–47]. The effects of the red yeast rice prod-
ucts are not consistent across these four RCTs. When 
the ‘red yeast rice product plus lifestyle’ intervention 
was compared with ‘placebo plus lifestyle’ interven-
tion, a more significant decrease of TC and LDL-C was 
found in the red yeast rice product group after treatment. 
However, there was no significant improvement in TC or 
LDL-C amongst those receiving the red yeast rice prod-
uct alone when compared to placebo alone. Amongst the 
rest four hyperlipidemia-focused RCTs, Danshen (丹参) 
[41–43], Juemingzi (决明子) [41–43], Zexie (泽泻) [41, 
43, 44], and/or Shanzha (山楂) [41, 43, 44] were the main 
constituents of the CHM formulas examined and three 
of these trials reported the significant between-group 
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effectiveness of the investigated CHM interventions on 
the decrease of TC, LDL-C, and/or TG levels [41, 43, 44] 
compared to control interventions. The sample size of 
the hyperlipidemia-focused RCTs ranged from 40 to 446. 
Only two hyperlipidemia-focused RCTs did not provide 
the age and gender profile of the participants in CHM 
and control groups [42, 46]. The duration of the trials 
ranged from 6 weeks to 12 months while one trial did not 
specify the study period.
All hyperlipidemia-focused RCTs reported safety-
related information and no deaths were noted. Three tri-
als specified their side effects in the CHM intervention 
groups, including heartburn/flatulence [40], diarrhea 
[42], and stomach upset [40, 44]. Three hyperlipidemia-
focused RCTs reported their study limitations including 
small sample size, lack of balanced baseline data between 
the CHM and control groups and no record of the par-
ticipants’ dietary control  [44, 45, 47]. As for risk of bias 
of the hyperlipidemia-focused RCTs, five trials did not 
use the random sequence generation method [41–43, 46, 
47], only two trials specified the appropriate allocation 
concealment [44, 45], and six trials failed to employ the 
blinding of outcome assessment [41–46].
Impaired glucose tolerance
The seven RCTs on CHM for the treatment of IGT origi-
nated from China (n = 6) [48–53] and Australia (n = 1) 
[54]. Amongst the IGT-focused RCTs, one compared 
‘CHM’ with ‘placebo’ [54], five compared ‘CHM plus 
lifestyle’ interventions with ‘lifestyle’ interventions alone 
[48–50, 52, 53], and one compared ‘CHM plus lifestyle’ 
intervention with ‘placebo plus lifestyle’ intervention [51]. 
The inclusion criteria regarding the 2hPG level remain 
stable (7.8–11.0  mmol/l) while the FPG level is either 
<7.0 or >7.0  mmol/l across all the IGT-focused RCTs. 
Additionally, all the tested CHM products within the 
IGT-focused RCTs are different. Despite the variation in 
the inclusion criteria and CHM products, the results on 
the effects of CHM interventions are consistent through-
out all IGT-focused trials. Specifically, more people with 
IGT reversed to normal in the CHM group (range 19.1–
63.1%) compared to those in the control group (range 
3.1–46.6%) and less people with IGT progressed to Type 
2 diabetes in the CHM group (range 6.2–22.2%) com-
pared to those in the control group (range 15.3–43.9%). 
Of the six IGT-focused RCTs with detailed CHM formu-
las, five reported the significant between-group effective-
ness of the investigated CHM interventions regarding the 
decrease of FPG, 2hPG, and/or HbA1c levels compared 
to control interventions [48, 49, 52–54] and Huanglian 
(黄连) and Gegen (葛根) were the only Chinese herbs 
both included in these five IGT-focused trials. The sam-
ple size of the IGT-focused RCTs ranged from 61 to 514, 
and all these RCTs provided the age and gender profile of 
participants in the CHM and control groups (897 males, 
939 females, mean age 53 years with the range from 47 to 
60 years). The duration of the IGT-focused trials ranged 
from 3 to 12 months.
All IGT-focused RCTs reported safety-related informa-
tion and no deaths were noted. The most common side 
effects reported in the CHM groups were dizziness, gas-
trointestinal reactions, and abdominal distension. Almost 
all IGT-related RCTs provided information on their study 
limitations including a short study period and short fol-
low-up period as well as small sample size. As for risk of 
bias of the IGT-focused RCTs, three trials provided infor-
mation about the allocation concealment [51, 52, 54], two 
trials provided details on the blinding of outcome assess-
ment [51, 54], and two trials reported double-blinding of 
participants and personnel [51, 54].
Obesity
Two RCTs on CHM for the treatment of obesity origi-
nated from China [55, 56] and one from Australia [57]. 
The three obesity-focused trials compared three differ-
ent CHM products with their placebos. BMI is the key 
indicator of the inclusion criteria of all obesity-focused 
RCTs included. However, the threshold value of BMI was 
set differently across these trials. Amongst the obesity-
focused RCTs, CHM products all showed more decrease 
of body weight than placebos after treatment. Green tea 
(绿茶) [55, 57] and Juemingzi (决明子) [56, 57] were the 
Chinese herbs included in two CHM formulas amongst 
these three obesity-focused trials. The sample size of the 
obesity-focused RCTs ranged from 78 to 134 and all these 
RCTs provided the age and gender profile of participants 
in the CHM and placebo groups. There were 115 males 
and 214 females across all the obesity-focused RCTs 
with a mean age of 40 years, ranging from 39 to 41 years. 
The duration of the obesity-focused trials ranged from 
7 weeks to 6 months.
All obesity-focused RCTs reported safety-related 
information and no death were noted. CHM interven-
tions were reported more side effects than the placebos, 
including nausea, headache, and skin rash. One obesity-
focused RCT indicated the study limitations including 
short study period, no follow-up period, and no true pla-
cebo group [56]. As for risk of bias of the obesity-focused 
RCTs, all trials reported the double-blinding of partici-
pants and personnel while these trials failed to provide 
any details of the blinding of outcome assessment.
Combined stroke risk factors
Six RCTs exploring the efficacy of CHM on one or more 
of the stroke risk factors were identified in the system-
atic review. Specifically, one trial examined the ‘CHM 
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plus lifestyle’ intervention for the treatment of ‘IGT and 
obesity’ compared to ‘placebo plus lifestyle’ interven-
tion, showing significant efficacy on both IGT and obe-
sity before and after treatment and a significant effect on 
obesity control between groups after treatment [58]; Two 
trials examined the ‘CHM plus biomedicine’ interven-
tions for the treatment of ‘diabetes and hyperlipidemia’ 
and ‘hypertension and hyperlipidemia’ compared to the 
‘biomedicine’ intervention [59] and ‘placebo plus bio-
medicine’ intervention [60], respectively—both of these 
studies found similar effect on the combined stroke risk 
factors between groups after treatment. Moreover, three 
trials examined the ‘CHM, biomedicine plus lifestyle’ 
interventions for the treatment of ‘metabolic syndrome’ 
[61], ‘hypertension and metabolic syndrome’ [62], and 
‘hypertension and obesity’ [63] compared to the ‘biomed-
icine plus lifestyle’ interventions with or without placebo, 
respectively, indicating significant effects on all included 
stroke risk factors by the CHM interventions compared 
to the control groups after treatment. Except the Bofu-
tsusho-san (防风通圣散) used in two trials, all the other 
CHM interventions involved exploring a combination 
of multiple stroke risk factors were different and there-
fore it is unable to report the commonly used Chinese 
herbs which are vital for the efficacy of combined stroke 
risk factors across these six RCTs. The sample size of the 
RCTs focused upon combined stroke risk factors ranged 
from 20 to 106, and two of these RCTs failed to provide 
the age and gender profile of participants in the CHM 
and control groups [58, 60]. The duration of the RCTs 
exploring the combined stroke risk factors ranged from 
4 to 6 months.
All RCTs focusing upon combined stroke risk fac-
tors reported safety-related information and no deaths 
were noted. Five out of these six RCTs reported that side 
effects only occurred in the CHM group [58, 60–63] 
including headache, dizziness, gastrointestinal reactions, 
and skin allergy. Only two RCTs focusing upon com-
bined stroke risk factors identified their study limitations 
[60, 63], including failure to double-blind the RCT, short 
study period and carry-over effect. As for risk of bias of 
the RCTs focusing upon combined stroke risk factors, 
no trial reported appropriate allocation concealment 
and blinding of outcome assessment, and two trials were 
found to have a high risk of bias regarding the random 
sequence generation [60, 61].
Discussion
This paper reports the first comprehensive system-
atic review of the literature concerning the use of CHM 
amongst people at greatest risk(s) of stroke. A number 
of significant findings from our review are important for 
future evidence-based planning and priority setting for 
research in stroke prevention.
Our analyses show some positive efficacy and safety 
evidence of varied CHM interventions in lowering high 
blood pressure, high blood glucose, high cholesterol, high 
body BMI and a combination of multiple stroke risk fac-
tors. Importantly, our findings indicate that, compared to 
biomedicine alone/lifestyle modification alone/biomedi-
cine plus lifestyle intervention, CHM monotherapy may 
be not sufficient enough for people to obtain their treat-
ment goals when treating hypertension, diabetes, and 
hyperlipidemia, while an intervention of CHM as a sup-
plement to biomedicine and/or a lifestyle intervention is 
more effective in lowering the levels of SBP/DBP, glucose, 
BMI, TC, 2hPG, and/or HbA1c. These findings from 
our review are in line with previous systematic reviews 
on CHM for cardiovascular diseases [12–14]. In addi-
tion, the evidence reported in the papers included with 
regards to the successful reversion from elevated blood 
glucose level to normal by using CHM interventions sug-
gests that some CHM products, in combination with a 
lifestyle intervention, could be considered a potential 
effective therapeutic regimen for IGT, and these findings 
are consistent with a Cochrane review on CHM for IGT 
published in 2009 [13]. Although many RCTs identified in 
our review demonstrate the therapeutic benefits of CHM 
in people with a number of stroke risk factors, there is 
a lack of replicable evidence on CHM use in combined 
stroke risk factors. It is worth noting that a CHM product 
(red yeast rice preparation), a medicinal food   [64], has 
been used several times not only for the management of 
hypertension but also for hyperlipidemia. However, the 
control interventions of all RCTs examining the efficacy 
of this rice preparation are different. Therefore, no trial 
included in our review paper has tested exactly the same 
CHM and control interventions for the treatment of any 
stroke risk factor(s).
Our findings show a large variation in the sample size 
and study period across the included RCTs. The poten-
tial risks of bias have been reported in the domains of 
allocation concealment, the blinding of participants and 
personnel, and/or the blinding of outcome assessment in 
the included RCTs. Most included trials have reported 
their safety information. No serious adverse events were 
noted although some studies showed some moderate side 
effects in the CHM groups.
Stroke risk factors vary by ethnic groups and such 
disparities may influence the etiology of stroke and the 
implementation of stroke prevention programs [65]. Nev-
ertheless, the majority of studies on CHM use for stroke 
risk factors included in this review were conducted in 
China on Chinese populations. As such, the results 
shown in our review paper may not always be directly 
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applicable to populations at risk of stroke in other coun-
tries beyond China. Furthermore, CHM is often com-
posed of a number of herbs and is prescribed based on 
the unique Chinese medicine theory—syndrome differ-
entiation. The replicability of these trial designs without 
Chinese medicine practitioners is therefore difficult.
There are some limitations to our systematic review 
that should be mentioned. Generalisability of the results 
from this systematic review is limited. Meanwhile, the 
overall ‘unclear’ reporting of research methodology in 
the included RCTs may limit the quality of the results 
reported in this review. In addition, our review was 
restricted to English peer-reviewed journal articles.
Conclusion
Although the findings in this systematic review with 
regards to the effect of CHM for stroke modifiable risk 
factors should be interpreted with caution, the potential 
therapeutic benefits of CHM as a treatment—particu-
larly in combination with biomedicine and/or lifestyle 
intervention—for different stroke risk factors needs to be 
further examined by conducting rigorous trials. Future 
research should be designed and implemented with ade-
quate sample size, detailed reporting of the allocation 
concealment method, sufficient application of double-
blinding with an adequate placebo and blinding of out-
come assessment, and long-term follow-up in different 
countries. Moreover, it is important for future research 
on this topic to pay attention to potential drug-herb 
interactions as a major safety issue in trial design when 
participants need to take one or more co-administered 
biomedicine as well as CHM products.
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